

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1734R1

Serial No.

09/546,857

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Cunningham et al.

Filing Date

10 Apr 2000

Group

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	08/691,794					02.08.96
	2	09/346,069					01.07.99
	3	6,020,473	01.02.00	Keyt et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
	4	WO 90/13649	15.11.90	PCT				
	5	WO 97/08313	06.03.97	PCT				
	6	WO 98/16551	23.04.98	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)


	7	Burgess and Maciag, "The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins" <u>Annu. Rev. Biochem.</u> 58:575-606 (1989)
	8	Cao et al., "Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR" <u>Journal of Biological Chemistry</u> 271(6):3154-3162 (Feb 9, 1996)
	9	Cunningham et al., "Interactions of FLT-1 and KDR with phospholipase C γ : identification of the phosphotyrosine binding sites" <u>Biochemical & Biophysical Research Communications</u> 240(3):635-639 (Nov 26, 1997)
	10	Dougher and Terman, "Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization" <u>Oncogene</u> 18(8):1619-1627 (Feb 25, 1999)
	11	Ferrara et al., "Pituitary Follicular Cells Secrete a Novel Heparin-binding Growth Factor Specific for Vascular Endothelial Cells" <u>Biochem. & Biophys. Res. Comm.</u> 161(2):851-858 (June 15, 1989)
	12	Ferrara et al., "The biology of vascular endothelial growth factor" <u>Endocrine Reviews</u> 18(1):4-25 (Feb 1997)
	13	Ferrara, N., "Vascular endothelial growth factor. The trigger for neovascularization in the eye" <u>Laboratory Investigation</u> 72(6):615-618 (1995)
	14	Fuh et al., "Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor" <u>Journal of Biological Chemistry</u> 273(18):11197-11204 (May 1, 1998)
	15	Gerber et al., "Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation" <u>Journal of Biological Chemistry</u> 273(46):30336-30343 (Nov 13, 1998)
	16	Ishikawa et al., "Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor" <u>Nature</u> 338:557-562 (1989)
	17	Ito et al., "Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules" <u>Journal of Biological Chemistry</u> 273(36):23410-23418 (Sep 4, 1998)
	18	Jin et al., "Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats" <u>Journal of Clinical Investigation</u> 98(4):969-976 (Aug 15, 1996)
	19	Keyt et al., "Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors: Generation of receptor-selective VEGF variants by site-directed mutagenesis" <u>Journal of Biological Chemistry</u> 271(10):5638-5646 (1996)
	20	Keyt et al., "The Carboxyl-terminal Domain (111-165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency" <u>Journal of Biological Chemistry</u> 271(13):7788-7795 (Mar 29, 1996)

Examiner

Date Considered

*Examiner. Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.

Paper # 6



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1734R1

Serial No.

09/546,857

Applicant

Cunningham et al.

Filing Date

10 Apr 2000

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)


21	Kunkel et al., "Efficient site-directed mutagenesis using uracil-containing DNA" <u>Methods in Enzymology</u> 204:125-139 (1991)
22	Landgren et al., "Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C- γ and migration of endothelial cells expressing Flt 1" <u>Oncogene</u> 16(3):359-367 (Jan 22, 1998)
23	Leung et al., "Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen" <u>Science</u> 246:1306-1309 (Dec 1989)
24	Maglione et al., "Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor" <u>Proc. Natl. Acad. Sci.</u> 88:9267-9271 (1991)
25	Malavaud et al., "Activation of Flk-1/KDR mediates angiogenesis but not hypotension" <u>Cardiovascular Research</u> 36(2):276-281 (Nov 1997)
26	Marte and Downward, "PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond" <u>Trends in Biochemical Sciences</u> 22(9):355-358 (Sep 1997)
27	Meyer et al., "A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases" <u>EMBO Journal</u> 18(2):363-374 (Jan 15, 1999)
28	Muller et al., "The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 Å resolution: multiple copy flexibility and receptor binding" <u>Structure</u> 5(10):1325-1338 (Oct 15, 1997)
29	Muller et al., "Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site" <u>Proc. Natl. Acad. Sci. USA</u> 94(14):7192-7197 (Jul 8, 1997)
30	Muller et al., "VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface" <u>Structure</u> 6(9):1153-1167 (Sep 15, 1998)
31	Ogawa et al., "A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain" <u>Journal of Biological Chemistry</u> 273(47):31273-31282 (Nov 20, 1998)
32	Olofsson et al., "Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells" <u>Proc. Natl. Acad. Sci. USA</u> 95(20):11709-11714 (Sep 29, 1998)
33	Park et al., "Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR" <u>Journal of Biological Chemistry</u> 269(41):25646-25654 (1994)
34	Polverini et al., "Assay and purification of naturally occurring inhibitor of angiogenesis" <u>Methods in Enzymology</u> 198:440-450 (1991)
35	Rousseau et al., "p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells" <u>Oncogene</u> 15(18):2169-2177 (Oct 1997)
36	Sawano et al., "Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor" <u>Cell Growth & Differentiation</u> 7(2):213-221 (Feb 1996)
37	Sawano et al., "The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLC γ " <u>Biochemical & Biophysical Research Communications</u> 238(2):487-491 (Sep 18, 1997)
38	Seetharam et al., "A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF" <u>Oncogene</u> 10(1):135-147 (Jan 5, 1995)
39	Tischer et al., "Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family" <u>Biochem. & Biophys. Res. Comm.</u> 165:1198-1206 (1989)
40	Waltenberger et al., "Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor" <u>Journal of Biological Chemistry</u> 269(43):26988-26995 (Oct 28, 1994)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1734R1

Serial No.

09/546,857

Applicant

Cunningham et al.

Filing Date

10 Apr 2000

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|----|--|
| 41 | Walter et al., "The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independent of N-linked glycosylation" <u>Laboratory Investigation</u> 74(2):546-556 (Feb 1996) |
| 42 | Wang and Keiser, "Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1" <u>Circulation Research</u> 83(8):832-840 (Oct 19, 1998) |
| 43 | Wells, "Systematic Mutational Analyses of Protein-Protein Interfaces" <u>Methods in Enzymology</u> 202:390-411 (1991) |
| 44 | Wennstrom et al., "Activation of phosphoinositide 3-kinase is required for PDGF-stimulated membrane ruffling" <u>Current Biology</u> 4(5):385-393 (May 1, 1994) |
| 45 | Wiesmann et al., "Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor" <u>Cell</u> 91(5):695-704 (Nov 28, 1997) |
| 46 | Wise et al., "Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1" <u>Proc. Natl. Acad. Sci. USA</u> 96(6):3071-3076 (Mar 16, 1999) |
| 47 | Yu and Sato, "MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor" <u>Journal of Cellular Physiology</u> 178(2):235-246 (Feb 1999) |

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.